Compounded semaglutide has not been banned in the United States as of this update, but the shortage-era allowance that made it widely available ended in 2025, and FDA has proposed a rule that would keep outsourcing facilities from compounding it [1] [4]. What’s left is narrow: a state-licensed pharmacy filling an individual patient’s prescription.
No ban, but the rules tightened in 2025
Semaglutide injection had been in shortage since 2022. On February 21, 2025, FDA determined “the shortage of semaglutide injection products … is resolved” [1]. That ended the legal basis for mass-produced copies.
FDA gave pharmacies time to wind down: 503A pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025. When a court denied the challengers’ preliminary injunction on April 24, 2025, FDA said the 503A grace period had ended [1]. Since then, a 503A pharmacy may compound semaglutide only for individual prescriptions, and not as copies of Ozempic or Wegovy “regularly or in inordinate amounts.” FDA won’t act on “four or fewer prescriptions” of a copy in a calendar month.
Beyond that limit, a prescriber has to document that the product “contains a change that produces a significant difference from the commercially available drug product for an identified individual patient” [1]. That’s the narrow lane compounded semaglutide travels in today.
Two kinds of compounders matter here. A 503A pharmacy is licensed by its state and fills prescriptions for named patients. A 503B outsourcing facility registers with FDA and can make larger quantities, but in most cases only from substances on FDA’s 503B bulks list or drugs on the shortage list [3]. The 2026 proposal concerns the second group.
| Date | Event | Source |
|---|---|---|
| 2022 | Semaglutide injection goes into shortage | FDA [1] |
| February 21, 2025 | FDA declares the semaglutide shortage resolved | FDA [1] |
| March 10, 2025 | FDA ties the grace periods to the court’s decision date | FDA [1] |
| April 22, 2025 | Stated end of the 503A grace period | FDA [1] |
| April 24, 2025 | Court denies a preliminary injunction; 503A grace period ends | FDA [1] |
| May 22, 2025 | 503B grace period ends | FDA [1] |
| April 1, 2026 | FDA reminder: semaglutide is on neither the 503B bulks list nor the shortage list | FDA [1] |
| April 30, 2026 | FDA proposes not to include semaglutide on the 503B bulks list | FDA [3] |
| May 1, 2026 | Proposal published in the Federal Register | Federal Register [4] |
| May 31, 2026 | FDA counts 990 adverse-event reports tied to compounded semaglutide | FDA [2] |
| June 26, 2026 | Comment period extended to July 30 | Federal Register [5] |
| July 30, 2026 | Extended comment period closes | Federal Register [5] |
| As of this update | No final 503B decision published | Federal Register |
Dates are FDA’s and the Federal Register’s own. A “proposal” is not a final rule.
What FDA proposed in 2026
On April 30, 2026, FDA announced it was “proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances” [3]. The formal notice ran in the Federal Register on May 1 [4], and the comment period was extended to July 30, 2026 [5].
What’s the bulks list? It’s FDA’s list of raw ingredients that 503B outsourcing facilities may compound from. In most cases, FDA says, they “cannot compound drugs using bulk drug substances unless the substance appears on the 503B bulks list, or the compounded drug is on the FDA’s drug shortage list” [3]. Semaglutide is on neither today [1]. FDA says it will consider the comments “before making a final determination.” No final notice has appeared as of this update.
Salt forms are already off-limits
One thing FDA has already settled: semaglutide sodium and semaglutide acetate. FDA says these salt forms “are different active ingredients than are used in the approved drugs” and that it is “not aware of any lawful basis for their use in compounding” [2]. If your pharmacy label says sodium or acetate, ask your prescriber about it before your next refill. Safety concerns in full are in is compounded semaglutide safe.
What a final decision would change, and what it wouldn’t
A final 503B exclusion would lock a door that’s already closed in practice. It wouldn’t, by itself, touch the 503A route that most online programs use. The table shows who’s affected.
| Who | Today | If FDA finalizes the exclusion |
|---|---|---|
| 503A pharmacy (state-licensed) | Patient-specific prescriptions; copies limited to four or fewer a month without a documented difference | Unchanged by the 503B list |
| 503B outsourcing facility | No current basis: off the shortage list and not on the bulks list | No bulks-list basis either, unless semaglutide returns to shortage |
| Brand Wegovy, Ozempic, Rybelsus | Sold under their approved labels | Unaffected |
| “Research use only” sellers | Illegal for human use | Still illegal |
Sources: FDA compounding policy page [1], FDA 503B proposal [3], FDA concerns page [2].
Could anything else end 503A compounding? Not on a known schedule. State pharmacy boards oversee 503A pharmacies, and FDA has warned companies that sold semaglutide illegally, including vials falsely labeled “for research purposes” [2]. Tirzepatide is in the same position, with an earlier timeline: see is compounded tirzepatide still available.
What to do if your supply changes
If your program stops offering compounded semaglutide, your prescriber can move you to a brand product. That switch, including the starting dose, is their call; don’t convert doses yourself. Self-pay brand prices are much lower than they were. Right now, NovoCare lists Wegovy pens at $199 a month for new patients at the two lowest doses, for two fills through December 31, 2026, then $349 a month [6]. The Wegovy pill starts at $149 a month.
How the Wegovy pill works, and whether it fits your routine, is in oral semaglutide. Compounded and brand costs side by side are in how much compounded semaglutide costs, and the legal routes to a prescription are in how to get compounded semaglutide.
How to tell a lawful program from a risky one
A lawful program has a licensed prescriber, a real intake and a named, state-licensed pharmacy. Some programs publish their pharmacy on their own site: Eden, Embody and MEDGm do. Whoever you use, check the pharmacy’s license with your state board. FDA’s red flags are worth running through too. Be wary of any company that [2]:
- says its compounded drug is the same as an FDA-approved drug
- offers deep discounts or prices that seem too good to be true
- sends medicine that looks different from before, or arrives damaged or without instructions
- doesn’t require a screening and prescription by a licensed doctor
- has no licensed doctor to answer questions after delivery
- prints spelling errors or a wrong pharmacy address on the label
- names a pharmacy you think might be fake
FDA has counted 990 adverse-event reports tied to compounded semaglutide through May 31, 2026, and says the real number is probably higher [2]. A 2025 secret-shopper study found some clinics sourcing from facilities without sterile-compounding licenses [7]. The pharmacy question is the one that protects you most. More on what compounded semaglutide is, and how programs compare, is in compounded semaglutide and on the compounded semaglutide providers scorecard.
What to ask your prescriber now
- Which pharmacy fills my prescription, and is it a 503A pharmacy licensed in my state?
- Is my semaglutide the base form, or a sodium or acetate salt?
- What documented reason makes a compounded product right for me instead of Wegovy?
- If the rules change, how would you move me to a brand product, and what would it cost?